Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Hycamtin receives positive opinion for treatment of patients with relapsed small cell lung cancer
January 5th, 2006
GlaxoSmithKline (GSK) announced that Hycamtin (topotecan powder for concentration for solution for infusion) received positive opinion from the European Committee for Human Medicinal Products (CHMP) for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom retreatment with the first-line regimen is not considered appropriate. Hycamtin is the first drug to receive a positive opinion from the CHMP for the treatment of relapsed SCLC, according to the company. The CHMP's positive opinion will now be proposed for final marketing approval by the European Commission. The product previously received approval in Europe for the...
Source: Women's Health Weekly (2006-01-05)
|
